Given the low response rate to Multi-targeted TKIs in RET-rearranged NSCLC, the next-generation RET-selective inhibitors, RXDX-105, BLU-667, and LOXO-292, are being tested. This evidence concerns the gene RET and non-small cell lung carcinoma.